TXG (10x) Company Current Liabilities

TXG (10xgenomics.com) - company brandmark

10x Genomics, Inc. (TXG) is protected by powerful patents in spatial biology and wields significant influence in IT-biotech. The company is developing cell study methods in collaboration with research centers to treat severe pathologies. This price chart, which confirms the market valuation, reflects debt dynamics currently standing at 0.01. The business is currently optimizing its model, seeking to increase profit through the sale of high-cost reagents.

TXG (10xgenomics.com) Short-Term Indebtedness history from 07/04/2022 to 10/30/2026

Financial and market metric breakdowns for 10x (TXG)

- share price and expert price forecast:
Stock Quotes 10x Genomics|TXG - Broker Consensus Forecast
- business market valuation indicators:
Market Valuation 10x Genomics, Inc.|TXG - Value Adjusted for Debt and Cash
- balance sheet net asset value indicators:
Book Value per Share 10x Genomics|TXG - Book Value of Business|Market Capitalization to Book Value Ratio 10xgenomics.com|TXG - Company Assets
- debt obligations and liquidity statistics:
Debt to Equity 10x Genomics, Inc.|TXG - Long-Term Debt to Capital Ratio|Short-Term Debt to Equity 10x Genomics, Inc.|TXG - Company Cumulative Debt|Debt to Book Capitalization Ratio 10x Genomics, Inc.|TXG - Company Long-Term Liabilities|Company Short-Term Debts 10x Genomics|Quick Ratio 10xgenomics.com
- net income and valuation multiples indicators:
TXG - Net Income
Basic company analysis:TXG - 10x Genomics
Mass-produced product of 10x Genomics, Inc.

As a portfolio manager, I assess asset liquidity through the lens of its short-term liabilities. The total amount of short-term debt consolidates all obligations maturing within one year, revealing the risks of cash flow gaps. The trend in this total short-term debt allows for the prompt adjustment of exposure prior to the publication of reports. For 10x Genomics, Inc. (TXG), such burdens are offset by a stable cash flow from the sale of consumables. This renders the company's capital structure resilient to external macroeconomic shocks.

Competitor analysis

TEM: Company Current Liabilities|QGEN (Qiagen NV) - Company Short-Term Indebtedness|IONS (Ionis Pharma) - Company Current Liabilities|Repligen Inc. - Company Short-Term Loans and Borrowings|RNA (Avidity Biosciences) - Company Short-Term Debts|CRSP - Short-Term Indebtedness|Company Short-Term Debts WGS|RARE - Short-Term Debt|Company Short-Term Debt Beam Therapeutics Corp BEAM|SRPT: Company Short-Term Indebtedness|TWST - Company Short-Term Debt|Short-Term Debt intelliatx.com|Stoke Therapeutics, Inc. (STOK) - Company Short-Term Debt|Company Current Liabilities BioLife Solutions Inc|WVE (Wave Life Sciences Corp) - Company Short-Term Debts|Maze Therapeutics Corp (MAZE) - Short-Term Debt Volume|Company Short-Term Debts SION|Company Current Liabilities primemedicine.com PRME|Company Short-Term Debt Taysha Gene Therapies, Inc. TSHA|Short-Term Debt Volume uniQure NV (QURE)|MGTX: Company Current Liabilities|Company Short-Term Loans and Borrowings RGNX (REGENXBIO Corp)|SLDB: Company Short-Term Debts|OCGN - Short-Term Debt Volume|Company Short-Term Debt PacBio|Company Short-Term Indebtedness BNTC (Benitec Biopharma Inc)|Company Short-Term Debts DSGN|Company Current Liabilities Rocket Corp RCKT|4D Molecular Therapeutics - Company Current Liabilities|Short-Term Debt Volume Lexeo Therapeutics Inc. (LXEO)|KRRO: Company Current Liabilities|Editas Medicine Inc - Amount of Current Liabilities|SLN (Silence Therapeutics Inc.) - Company Current Liabilities|Company Short-Term Indebtedness PRQR|CDXS (Codexis Inc) - Company Short-Term Debts|SGMO - Short-Term Indebtedness|Company Short-Term Debts NAUT|Metagenomi Inc. - Company Short-Term Indebtedness|Company Short-Term Debt Precision BioSciences DTIL|GBIO: Company Short-Term Indebtedness|Boundless Bio, Inc. - Company Short-Term Debts|XCUR - Company Short-Term Debts|IMNN: Company Short-Term Debts|PHIO: Amount of Current Liabilities|Company Current Liabilities MBIO|Company Short-Term Indebtedness RNAZ (TransCode)|Company Current Liabilities BNGO (Bionano Genomics, Inc.)|APDN (adnas.com) - Company Short-Term Loans and Borrowings|Company Short-Term Debts BLUE (bluebird bio)|Short-Term Indebtedness ImmunoPrecise Antibodies Ltd|Omega - Company Short-Term Debts|Short-Term Debt Singular Genomics Corp|Regulus Therapeutics (RGLS) - Company Short-Term Debt|Company Short-Term Indebtedness SYRS|Company Short-Term Debt Telesis Bio|Short-Term Debt TRACON Pharmaceuticals Inc. TCON|Company Short-Term Debt Unity Bio (UBX)